Infectious Disease Diagnostics Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 45.24 Billion |
| Market Size (2029) | USD 53.68 Billion |
| CAGR (2024 - 2029) | 3.48 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Infectious Disease Diagnostics Market Analysis
The Infectious Disease Diagnostics Market size is estimated at USD 45.24 billion in 2024, and is expected to reach USD 53.68 billion by 2029, growing at a CAGR of 3.48% during the forecast period (2024-2029).
The market for infectious illness diagnostics was considerably affected by the COVID-19 pandemic. The market under study benefited from the high infection rates among COVID-19 patients. For instance, in February 2022, Mylab Discovery Solutions released CoviSwift, a point-of-care (POC) RT-PCR testing system that may be used in small labs, in-hospital labs, airports, and communities. Additionally, in March 2020, BioMedomics released PoC COVID-19 test that can detect antibodies in blood within 15 minutes. Furthermore, in March 2020, Abbott introduced the RealTime SARS-CoV-2 assay, a PCR-based test for diagnosing COVID-19. As the incidence of coronavirus increased, there was a greater need for diagnostic tools for infectious diseases during the pandemic. Additionally, many diagnostic labs and testing facilities opened, which broadened the market's potential. For instance, in June 2020, the Union Minister of Health and Family Welfare introduced India's first mobile I-Lab (Infectious disease diagnostic lab) for COVID-19 testing. Hence, in the early phase, COVID-19 impacted the market considerably; however, currently, the demand for diagnostic tools for infectious diseases has slowed down and is expected to have stable growth during the forecast period of the study.
The rising prevalence of infectious diseases, the shift in emphasis from centralized laboratories to point-of-care testing, and rising R&D activity on infectious disease diagnostics are other important drivers of market expansion. Rapid diagnostics for the detection of diseases are evolving as a result of scientific research and development efforts in developing novel technologies and techniques, including mass spectrometry and next-generation sequencing (NGS), fueling market expansion. For instance, according to an article by Frontiers in February 2022, non-typhoidal Salmonella is a common cause of bacterial enteritis in humans. It causes almost 93.8 million cases of gastroenteritis globally each year. The increasing preference of end users for point-of-care testing is also projected to fuel market expansion. Point-of-care diagnostics offer quick, useful information for patient care where the disease is being experienced. As a result, several firms are concentrating on research and development initiatives to create point-of-care diagnostic solutions for developing nations. The major firms are constantly updating their product lines through introducing new goods, joint ventures with third parties, mergers, and acquisitions, all of which will contribute to the worldwide study market's expansion. For instance, in December 2021, Roche launched the first infectious disease tests on the Cobas 5800 System, a new molecular laboratory instrument, in countries accepting the CE mark. Similarly, in May 2021, Torus Biosystems revealed the USD 25 million series financing to advance infectious disease diagnostics across healthcare settings.
Thus, factors such as the rising prevalence of infectious diseases and increasing initiatives by major market players are expected to drive market growth over the forecast period. However, inadequate reimbursements and rising healthcare costs limiting the use of novel diagnostic techniques are restraining the market's growth.
Infectious Disease Diagnostics Market Trends
This section covers the major market trends shaping the Infectious Disease Diagnostics Market according to our research experts:
The Human Immunodeficiency Virus (HIV) Segment is Expected to Hold a Significant Share of the Market Over the Forecast Peiod
The human immunodeficiency virus segment is anticipated to witness significant growth during the forecast period of the study. The Minority of HIV/AIDS Fund (MHAF), United States Department of Health and Human Services Statistics, updated in June 2021, estimates that approximately 37.6 million people are living with HIV worldwide in 2020, of whom 35.9 million were adults and 1.7 million were children (under the age of 15). According to the same source, 1.5 million people will have contracted HIV globally in 2020. The market is expanding due to the rising prevalence of HIV and the demand for diagnostic tests and detection.
Additionally, in August 2021, the Human Rights Campaign (HRC) Foundation and "Us Helping Us" started the first in-home HIV testing program for residents in the United States. It is anticipated that the increased awareness about HIV and rising initiatives taken by various organizations worldwide will support the market growth during the forecast period.
It is also anticipated that new research and developments, technological advancements, and the introduction of technologically enhanced goods by key competitors will accelerate the market's expansion. For instance, in April 2021, Altona Diagnostics One introduced an in-vitro diagnostic test that identifies and quantifies the human immunodeficiency virus (HIV) specific RNA in human plasma. It was based on real-time RT-PCR technology, and the test was known as the 1.5 AltoStar HIV RT-PCR Kit.
Therefore, due to increasing HIV infections, new research and developments, and technological advancements, the Human Immunodeficiency Virus (HIV) segment is expected to witness significant growth over the forecast period.
North America is Anticipated to Observe Significant Market Growth Over the Forecast Period
North America, is expected to hold a significant share of the market. The major factors contributing to the market growth are the increasing prevalence of infectious diseases, high expenditure on healthcare, and an increase in awareness among the population regarding the availability of diagnostic devices. For instance, according to information released by CDC, the 2021 flu season resulted in 9 million illnesses, 4 million medical visits, and 10,000 hospitalizations in the United States. In the upcoming years, market growth is predicted to be positively impacted by the rising burden of diseases.
In addition, in June 2021 the FDA registered Dipanjan Pan's laboratory at the University of Maryland School of Medicine (UMSOM) as an approved laboratory development site for RNA Disease Diagnostics Inc.'s Antisense COVID-19 molecular diagnostic test. The market is therefore anticipated to have significant expansion in the region over the course of the projected period in light of the aforementioned considerations.
Additionally, the market expansion in the nation will be accelerated by strategic activities including collaborations, acquisitions, grant programmes, and others. For instance, in July 2021, Omega Specialty Nurses (OSN), House of Sophrosyne, and the Viral Hepatitis Care Network in Ontario have received grants from the 2021 CONNECT-C Grant Program from Gilead Sciences Canada, Inc. to expand the number of hepatitis screening centres across the nation. This is expected to improve the diagnosis of disease and adaptability of product and thus drives the market.
The market is also driven by expanding investments for improving disease model analysis. To develop linkages between the academic community, business community, and the governmental sector. For instance, in April 2021, the government of Canada formed five multidisciplinary infectious disease modelling networks with a total expenditure of USD 10 million. The findings will enable Canada to better respond to potential threats to public health, which will spur the industry to expand. The coordination of infectious disease modelling will also be considerably improved.
Therefore, due to factors such as increasing prevalence of infectious diseases, expanding investments for improving disease model analysis, and strategic activities including collaborations, acquisitions, grant programmes, and others, the growth of the studied market is anticipated in the North American region.
Infectious Disease Diagnostics Industry Overview
The infectious disease diagnostics market is highly fragmented, with several global and international players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some key players in the market are Danaher Corporation, Veracyte Inc., Abbott Laboratories, BioMérieux SA, F. Hoffmann-La Roche Ltd, and Becton, Dickinson and Company.
Infectious Disease Diagnostics Market Leaders
-
BioMérieux SA
-
F. Hoffmann-La Roche Ltd
-
Abbott Laboratories
-
Becton, Dickinson and Company
-
DiaSorin SpA (Luminex)
*Disclaimer: Major Players sorted in no particular order
Infectious Disease Diagnostics Market News
- July 2022: F. Hoffmann-La Roche Ltd launched a new dual antigen and antibody diagnostic test for hepatitis C. The new Elecsys HCV Duo is one the first commercially available immunoassay test that allows the simultaneous and independent determination of the hepatitis C virus strain from a single human plasma or serum sample.
- February 2022: SEEGENE received the CE-IVD mark from the EU regulatory authority for their Allplex SARS-CoV-2 rapid MDx Assay. This assay is appropriate for use in airports, schools, and other large-scale institutions since it has the capacity to produce results in less than 30 minutes.
Infectious Disease Diagnostics Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Prevalence of Infectious Diseases
- 4.2.2 Shift in Focus from Centralized Laboratories to Decentralized Point-of-Care Testing
- 4.2.3 Research on Infectious Disease Diagnostics
-
4.3 Market Restraints
- 4.3.1 Inadequate Reimbursements
- 4.3.2 Rising Healthcare Costs Limiting the Use of Novel Diagnostic Techniques
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size By Value- USD million)
-
5.1 By Application
- 5.1.1 Hepatitis
- 5.1.2 Human Immunodeficiency Virus (HIV)
- 5.1.3 Chlamydia Trachomatis Genital Infection and Gonorrhea (CT/NG)
- 5.1.4 Hospital-acquired Infections
- 5.1.5 Human Papillomavirus (HPV)
- 5.1.6 Tuberculosis (TB)
- 5.1.7 Influenza
- 5.1.8 Other Infectious Diseases
-
5.2 By Product
- 5.2.1 Assays, Kits, and Reagents
- 5.2.2 Instruments
- 5.2.3 Services and Software
-
5.3 By Technology
- 5.3.1 Polymerase Chain Reaction (PCR)
- 5.3.2 Isothermal Nucleic Acid Amplification Technology (INAAT)
- 5.3.3 Immunodiagnostics
- 5.3.4 DNA Microarray
- 5.3.5 Clinical Microbiology
- 5.3.6 DNA Sequencing and Next-Generation Sequencing (NGS)
- 5.3.7 Other Technologies
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Biomérieux SA
- 6.1.2 Abbott Laboratories
- 6.1.3 Becton, Dickinson and Company
- 6.1.4 Bio-Rad Laboratories
- 6.1.5 Danaher Corporation
- 6.1.6 F. Hoffmann-La Roche AG
- 6.1.7 Siemens Healthineers
- 6.1.8 Thermo Fisher Scientific
- 6.1.9 Quidel Corporation
- 6.1.10 DiaSorin SpA (Luminex)
- 6.1.11 Trinity Biotech PLC
- 6.1.12 Quest Diagnostics
- 6.1.13 Sysmex Corporation
- 6.1.14 Ortho Clinical Diagnostics
- 6.1.15 Seegene Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityInfectious Disease Diagnostics Industry Segmentation
As per the scope of the report, infectious disease diagnostics involve identifying the presence of foreign antigens/organisms using diagnostic tools such as kits and devices.
The Infectious Disease Diagnostics Market is segmented by application (Bacterial Infection, Cardiovascular Infection, CNS Infections, fungal Infection, Gastrointestinal Infection, Sexually Transmitted Disease, Viral Infection, and Other Applications), product (Assays, Kits, and Reagents, Instruments, and Services and Software), technology (Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), immunodiagnostics, DNA microarray, clinical microbiology, DNA sequencing and next-generation sequencing (NGS), and other technologies), and geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The report offers the value (in USD million) for the above segments.
| By Application | Hepatitis | |
| Human Immunodeficiency Virus (HIV) | ||
| Chlamydia Trachomatis Genital Infection and Gonorrhea (CT/NG) | ||
| Hospital-acquired Infections | ||
| Human Papillomavirus (HPV) | ||
| Tuberculosis (TB) | ||
| Influenza | ||
| Other Infectious Diseases | ||
| By Product | Assays, Kits, and Reagents | |
| Instruments | ||
| Services and Software | ||
| By Technology | Polymerase Chain Reaction (PCR) | |
| Isothermal Nucleic Acid Amplification Technology (INAAT) | ||
| Immunodiagnostics | ||
| DNA Microarray | ||
| Clinical Microbiology | ||
| DNA Sequencing and Next-Generation Sequencing (NGS) | ||
| Other Technologies | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Infectious Disease Diagnostics Market Research FAQs
How big is the Infectious Disease Diagnostics Market?
The Infectious Disease Diagnostics Market size is expected to reach USD 45.24 billion in 2024 and grow at a CAGR of 3.48% to reach USD 53.68 billion by 2029.
What is the current Infectious Disease Diagnostics Market size?
In 2024, the Infectious Disease Diagnostics Market size is expected to reach USD 45.24 billion.
Who are the key players in Infectious Disease Diagnostics Market?
BioMérieux SA, F. Hoffmann-La Roche Ltd, Abbott Laboratories, Becton, Dickinson and Company and DiaSorin SpA (Luminex) are the major companies operating in the Infectious Disease Diagnostics Market.
Which is the fastest growing region in Infectious Disease Diagnostics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Infectious Disease Diagnostics Market?
In 2024, the North America accounts for the largest market share in Infectious Disease Diagnostics Market.
What years does this Infectious Disease Diagnostics Market cover, and what was the market size in 2023?
In 2023, the Infectious Disease Diagnostics Market size was estimated at USD 43.72 billion. The report covers the Infectious Disease Diagnostics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Infectious Disease Diagnostics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Infectious Disease Diagnostics Industry Report
The Global Infectious Disease Diagnostics Market is segmented by application, product, technology, and geography. The market size and market share are crucial metrics in understanding the industry report. The market report provides valuable insights into the global market, including market analysis and market research. The industry report highlights the market trends and market growth, offering a comprehensive market forecast and industry overview. The market leaders are identified in the industry analysis, providing a clear picture of the industry outlook.
The market segmentation includes bacterial infection, cardiovascular infection, CNS infections, fungal infection, gastrointestinal infection, sexually transmitted disease, viral infection, and other applications. The product segment covers assays, kits, and reagents, instruments, and services and software. The technology segment includes polymerase chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), immunodiagnostics, DNA microarray, clinical microbiology, DNA sequencing and next-generation sequencing (NGS), and other technologies. The geography segment spans North America, Europe, Asia-Pacific, Middle East, and Africa, and South America.
The report example provides an in-depth market review, highlighting the industry sales and industry size. The market outlook and market predictions offer a detailed market overview, including market data and industry statistics. The industry research and industry trends are essential for understanding the market value and market segmentation. The report pdf serves as a comprehensive guide for research companies, providing valuable industry information and insights into the market forecast and market growth rate.
